Sree Chitra Tirunal Institute develops an anti cancer anti-inflamatory drug conjugated to human serum Albumin
Published: March 25, 2019
The Sree Chitra Tirunal Institute of Medical Sciences and Technology (SCTIMST) has recently developed an anti cancer anti-inflamatory drug conjugated to the human serum Albumin. It is an intravenous delivery system, enabling 100 fold increase in drug bio-availability and is a mix of human serum albumin and a plant based drug. This combination is the first of its kind as human albumin which is more compatible to the human body is being used. Clinical trials in humans have to be completed and results assessed as the ensuing steps towards commercialisation. The institute has also developed the technology of isothermal based DNA amplification device to detect TB bacterium in sputum samples in less than 30 minutes. Nearly 2-3 million people are infected with Tuberculosis and the prevalence of totally drug resistant TB (TDR-TB) is very high in India. The TB screening device employs a nucleic acid amplification technique to detect TB in less than 30 minutes with high specificity and without false positives. It can simultaneously screen 20 patient samples in one assay and at considerably lower cost than the existing devices ( costs approx Rs 2500/ sample). The device will also help in mass screening of population of people for TB at a substantially low cost.
Topics: Albumin • Branches of biology • Extensively drug-resistant tuberculosis • Infectious diseases • Medical specialties • Polymerase chain reaction • Serum • Totally drug-resistant tuberculosis • Tuberculosis • Tuberculosis in India